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Abstract
Background
Plasmodium knowlesi is the most common cause of malaria in Malaysian Borneo, with
reporting limited to clinical cases presenting to health facilities and scarce data on the true
extent of transmission. Serological estimations of transmission have been used with other
malaria species to garner information about epidemiological patterns. However, there are a
distinct lack of suitable serosurveillance tools for this neglected disease.
Methodology/Principal findings
Using in silico tools, we designed and expressed four novel P. knowlesi protein products to
address the distinct lack of suitable serosurveillance tools: PkSERA3 antigens 1 and 2,
PkSSP2/TRAP and PkTSERA2 antigen 1. Antibody prevalence to these antigens was
determined by ELISA for three time-points post-treatment from a hospital-based clinical
treatment trial in Sabah, East Malaysia (n = 97 individuals; 241 total samples for all time
points). Higher responses were observed for the PkSERA3 antigen 2 (67%, 65/97) across
all time-points (day 0: 36.9% 34/92; day 7: 63.8% 46/72; day 28: 58.4% 45/77) with signifi-
cant differences between the clinical cases and controls (n = 55, mean plus 3 SD) (day 0
p<0.0001; day 7 p<0.0001; day 28 p<0.0001). Using boosted regression trees, we devel-
oped models to classify P. knowlesi exposure (cross-validated AUC 88.9%; IQR 86.1–
91.3%) and identified the most predictive antibody responses.
Conclusions/Significance
The PkSERA3 antigen 2 had the highest relative variable importance in all models. Further
validation of these antigens is underway to determine the specificity of these tools in the con-
text of multi-species infections at the population level.
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Author summary
Malaria caused by Plasmodium knowlesi is the most common form of the disease in
Malaysia. The parasite is transmitted from monkeys to humans via the bite of an infected
mosquito, with the resulting P. knowlesi infection potentially leading to severe symptoms
and in some cases, death. Although adult males working close to areas with infected mon-
keys are at the greatest risk of infection, the true extent of the geographical boundaries of
P. knowlesi transmission is as yet unknown. The ability to measure antibodies to infection
is a powerful technique that would help to address this deficit. However, currently avail-
able recombinant proteins lack the required specificity for this role. Here, we have devel-
oped a panel of recombinant proteins for eventual use as serological tools, strongly
supported by robust statistical methods. We envisage that these tools will complement
existing approaches to identifying the geographical limits of P. knowlesi transmission.
Introduction
Plasmodium knowlesi is a simian parasite which can cause zoonotic malaria in humans [1].
Recent evidence suggests that human P. knowlesi infections are a growing public health threat
in South East Asia, particularly in Malaysia [2]. P. knowlesi has the potential to cause severe
disease in endemic regions [3], and is now the most common cause of clinical malaria in
Malaysia [4]. P. knowlesi is morphologically similar to P. malariae [5], historically leading to
the misdiagnosis of P. knowlesi infections as P. malariae [6]. Recent publications have also
demonstrated misdiagnosis of P. knowlesi as P. vivax and P. falciparum [7, 8] with potential
delay of appropriate treatment associated with case fatalities [3, 9, 10]. Studies have shown that
antibodies to Plasmodium proteins persist for long periods [11], even in the context of limited
exposure or absence of infection. Such antibodies can be utilised in serological assays, accu-
rately estimating the incidence and exposure to Plasmodium parasites [12, 13].
One key requirement for serological studies is the identification of Plasmodium species-spe-
cific biomarkers, particularly in regions where multi-species infections are likely to occur. It is
important to distinguish between human serological responses to different Plasmodium spe-
cies to improve our understanding of immunity to these infections, as well as define the geo-
graphical spread of infection. Such information can also help to evaluate the impact of how
control measures targeting a single species might affect the transmission and immunological
profile of other co-endemic species. The few recombinant protein reagents that do exist for P.
knowlesi have a high level of sequence homology with orthologues from other Plasmodium spe-
cies and, as such, are not applicable to identifying species-specific antibody responses. For
example, PK66 (PkAMA1) [14] and PkSPATR (secreted protein with altered thrombospondin
repeat) [15] share 86% and 85% amino acid identity respectively with P. vivax (https://is.gd/
MzISez), potentially making it difficult to distinguish between the two species where infections
are co-endemic.
The 2011 WHO consultation panel on the public health importance of P. knowlesi recom-
mended the urgent development of P. knowlesi-specific diagnostic tools [16]. Key to achieving
this goal would be the development of sensitive and accurate tools to help monitor the trans-
mission of infection.
In this study, we describe the development and evaluation of a panel of novel recombinant
antigens based on P. knowlesi-specific amino acid sequences, using publicly available in silico
tools. The development of such well-validated species-specific tools represent a potentially
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important serosurveillance tool to help monitor for historical P. knowlesi infections in endemic
areas. To illustrate how these data can be used to identify seropositive individuals, we utilise
data-adaptive statistical methods (boosted regression trees) to classify exposed individuals. By
assessing relative variable importance within these models, we identify the antigen responses
contributing most to model predictions and potential serological tools for use in epidemiologi-
cal studies. These reagents will also serve as an important set of tools to help identify correlates
of immunity to P. knowlesi.
Methods
Identification and screening of target sequences
Fig 1 outlines the experimental strategy used in the identification of the target sequences of
interest. Known markers of seroincidence were selected based on available evidence from P.
falciparum: AMA1 [17], MSP1 [18], SSP2/TRAP [19] and SERA [20] (PkAMA1 (PKNH_093
1500), PkMSP1 (PKNH_0728900), PkSSP2/TRAP (PKNH_1265400), SERA3 (PKNH_0413
400) and TSERA2 (PKNH_0413500), respectively). Full-length protein sequences for each
gene were initially screened using the BlastP search tool (Plasmodb: https://is.gd/XOs7vd [21]
and NCBI: https://is.gd/MzISez). Amino acid sequences were used to generate maximum like-
lihood phylograms to summarise the relatedness of each gene target between species (S1A–
S1E Fig). Alignments were also generated for each target using amino acid sequences from
other plasmodia matching the query sequence using the MUltiple Sequence Comparison by
Log-Expectation (MUSCLE) software (http://www.ebi.ac.uk/Tools/msa/muscle/) [22] (S2A–
Fig 1. Flowchart summarising the experimental strategy used in the identification and validation of the P. knowlesi-specific candidates.
https://doi.org/10.1371/journal.pntd.0006457.g001
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S2E Fig). Each alignment was then interrogated to identify regions of identity primarily with
P. vivax and P. falciparum but also with P. malariae and P. ovale. Regions or entire sequences
showing high levels of identity were excluded from further analysis and the P. knowlesi-specific
truncated regions were again screened using BlastP to validate sequence specificity (Fig 1 and
S1 Table). Each target sequence was analysed using domain prediction software (http://
gene3d.biochem.ucl.ac.uk/ and http://smart.embl-heidelberg.de/) to help define putative
domain boundaries, where possible. The aim was to limit the level of potential antibody cross-
reactivity, which would limit the usefulness of the antigens as serological tools due to the high
level of identical amino acids between species. A particular problem in co-endemic settings.
Simultaneously, sequences were also screened using the TMHMM server (http://www.cbs.dtu.
dk/services/TMHMM/) to help confirm the presence, or absence, of signal peptides and trans-
membrane regions. Previous experience from our group and others has shown that the pres-
ence of signal peptides and/or transmembrane domains can significantly impede protein
expression and solubility [23]. Based on this, each confirmed target construct was designed to
exclude both the signal peptide and transmembrane domains, which in addition to the GST
solubility tag was designed to aid expression of soluble proteins [24].
An additional selection criteria step was to determine the transcriptional status of the candi-
date genes. Blood stage messenger RNA was collected and analysed using the human red
blood cell culture adapted P. knowlesi A1-H1 line [25], grown in human blood obtained from
the United Kingdom National Blood Transfusion Service. First strand synthesis was carried
out using SuperScript IV Reverse Transcriptase (RT) (Thermo Fisher Scientific) using oligo d
(T)20 for priming (RT+) according to the manufacturer’s instructions. As a negative control
(RT-), a second identical reaction was set up in parallel without the addition of the SuperScript
IV RT. For PCR analysis of cDNA transcripts, RT+ and RT- samples were used as templates
for transcript specific PCR primers for the candidate gene sequences alongside genomic DNA
controls. In addition, both PkCTRP (circumsporozoite protein and thrombospondin-related
adhesive protein [TRAP]-related protein) and PkCSP (circumsporozoite protein), both shown
to be pre-erythrocytic stage targets, were included in the panel as negative controls. Where
possible, primer pairs were designed to flank introns so that amplicons from cDNA and
gDNA could be distinguished. Sequences of primer pairs used to amplify each transcript are
listed in S2 Table alongside the expected cDNA and gDNA amplicon size. Amplicons were
PCR amplified using GoTaq Green Master Mix (Promega) and analysed on a 1.2% agarose gel
(S3 Fig).
Cloning and expression of Plasmodiumknowlesi-specific recombinant
antigens in Escherichia coli
Four new constructs were designed (Table 1 and Fig 2) based on three genes. Two sequences
within SERA3 (PKNH_0413400; nucleotide positions 73–419 (Antigen 1) and 2476–2994
(Antigen 2) based on the reference P. knowlesi H strain), SSP2/TRAP (PKNH_1265400; nucle-
otide positons 1141–1500) and TSERA2 (PKNH_0413500; nucleotide positons 178–751 (Anti-
gen 1)) and were PCR amplified from P. knowlesi genomic DNA (H strain). Vector compatible
primers were designed for each completed target sequence (S3 Table). Cloning of amplified
sequences is as described previously [26]. Briefly, purified inserts were cloned into a TA vector
(pGEM-T Easy, Promega) and sequence verified. Correct sequences were restriction digested
and sub-cloned into a GST expression vector (pGEX-2T, GE Healthcare) and sequence veri-
fied before transforming into BL21 (DE3) Escherichia coli expression cells (Novagen). Vali-
dated expression clones were expressed automatically using an autoinduction media based on
established protocols [27]. Following expression, protein purification was as described [28].
Novel P. knowlesi serological tools
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Briefly, GST-tagged proteins from clarified bacterial lysate were purified by affinity chroma-
tography (Glutathione sepharose 4B; GE Healthcare) and fractions from each protein analysed
(Bradford assay reagent, BioRad) to identify protein-containing fractions. Pooled protein posi-
tive fractions were dialysed against PBS and the protein content quantified (Bicinchoninic acid
assay (BCA), Thermo Fisher). The dialysed purified proteins were analysed on a 4–20% gradi-
ent gel (NuPAGE Bis-Tris acetate) under denaturing conditions and visualised using the Coo-
massie blue staining method (BioRad BioSafe, USA) (Fig 3).
The empirical sizes of each protein were calculated using the ImageLab (BioRad) software
with the PageRuler prestained marker (Fermentas) as a reference standard (Table 1).
SNP and phylogenetic analysis
Full-length sequence data from Plasmodb and construct-specific truncated sequences gener-
ated in-house using Sanger sequencing were mapped to an in-house reference sequence strain
(Pk-H strain) using the Burrows-Wheeler Aligner (BWA) software (v0.7.5a-r405) [32]. Single
nucleotide polymorphisms (SNPs) (S4–S8 Tables) were called using the SAMtools (v1.3)
(Sequence Alignment/Map) software using default settings [33] and were filtered to increase
stringency and target only high quality variants (missingness<10%, mixed calls<10%). Cus-
tom Perl scripts identified overlap between these SNPs and each gene candidate. Variants were
annotated using snpEFF (v4.3i) (http://snpeff.sourceforge.net/) [34] to retrieve the amino acid
position and type effect of the variant. Maximum likelihood phylogenetic trees were con-
structed from protein sequences using RAxML [35] with a fixed empirical substitution matrix
and 200 bootstraps and was visualised using iTOL (http://itol.embl.de) [36].
Enzyme-linked immunosorbent assay (ELISA) and sera collection
The indirect enzyme-linked immunosorbent assay was performed to screen for antibodies to
P. falciparum, P. vivax and P. knowlesi antigens using previously described methods [37].
Briefly, antigens were coated at 50 ng/well and serum samples (diluted from frozen serum
stocks) assayed at 1/1000 dilution for both the P. knowlesi recombinants and the PvMSP1-19
(donated as a kind gift from Tony Holder) positive control antigen. Polyclonal rabbit anti-
Table 1. Summary of recombinant antigen construct characteristics.
Gene ID Antigen Description Chromosome AA
position
Expression
(mg/L)
Size (kDa)
Predicted Empirical
PKNH_0413400 SERA3
ag1
cysteine protease (Serine repeat-like antigen) 4 25–140 20.5 w/
GST
37.7 49.6
(118.9)
w/o
GST
11.3 n/a
PKNH_0413400 SERA3
ag2
cysteine protease (Serine repeat-like antigen) 4 826–998 15 w/
GST
44.9 68.7
(162.7)
w/o
GST
18.4 n/a
PKNH_1265400 SSP2/
TRAP
sporozoite surface protein 2, putative,
thrombospondin-related anonymous protein (TRAP)
12 381–500 17 w/
GST
39.7 53.1
(132.5)
w/o
GST
13.2 n/a
PKNH_0413500 TSERA2
ag1
Truncated cysteine protease 4 60–251 11.9 w/
GST
46.8 59.7
(117.9)
w/o
GST
20.4 n/a
https://doi.org/10.1371/journal.pntd.0006457.t001
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human IgG-HRP (Dako, Denmark) was used at 1/15,000 dilution and plates were developed
using TMB (One component HRP microwell substrate, Tebu-bio). All assays were performed
in duplicate. Negative and positive controls, including blank (buffer only) wells were used to
help standardise across assay runs. Values in excess of 1.5 CV between duplicates were consid-
ered fails and re-ran.
Written informed consent was obtained from all study participants [18, 38]. Samples were
collected as part of a hospital-based clinical trial in Malaysia, Sabah (www.clinicaltrials.gov:
#NCT01708876) (Fig 1) [38]. Serum samples were collected at Day 0 (n = 92), 7 (n = 72) and
28 (n = 77) following hospital admission, with drug treatment also taking place at Day 0. The
human research ethics committees of Malaysia (MREC) (#NMRR-12-537-12568), the Menzies
Fig 2. Plasmodiumknowlesi-specific recombinant antigen constructs. Schematic representations for each protein are shown with key features labelled. (a) PkSERA3
shows the location of the putative pro-enzyme and enzyme domains. The predicted subtilisin (SUB) 1 cleavage sites in relation to variable regions 1 and 2 and the
cytoplasmic domain [29]. (b) PkSSP2/TRAP contains a von Willebrandt A domain (vWA), thrombospondin type (TSP) 1 motif, a C-terminal transmembrane (TM)
region and a cytoplasmic terminal domain (CTD). Putative T-cell and B-cell epitopes are highlighted with an asterix or black square, respectively [30]. (c) PkTSERA2
shows the lack of central enzyme domain due to truncation of the sequence [29]. Predicted secondary structures generated in I-Tasser [31] are shown above each
scheme. Red boxes represent helices, blue arrows sheets and the black line coils. The position of recombinant proteins are highlighted below each scheme with the N-
and C-terminal amino acid positions indicated. The overall length of each protein is referenced by the amino acid ruler above each secondary structure prediction. For
all proteins SP refers to the signal peptide.
https://doi.org/10.1371/journal.pntd.0006457.g002
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School of Health and Research (Australia) (#HREC-2012-1814) and the London School of
Hygiene and Tropical Medicine (UK) (#6244) approved the study. Twenty-six P. vivax-posi-
tive Ethiopian samples [18] based on positive responses to PvAMA1 and PvMSP1-19 were
used as the P. vivax-positive, P. knowlesi-negative control group. In addition, 29 malaria naïve
(Public Health England; LSHTM ethics approval #11684) serum samples were used as the P.
knowlesi-negative control group. For the scatterplot presented in Fig 4, both negative control
groups were compared to the responses from the P. knowlesi-exposed hospital clinical case
samples. All samples used in the study were anonymised.
Statistical and sequence analysis
Descriptive analysis of serological data was performed using STATA/IC 14.2 (StataCorp LP,
USA) and PRISM (GraphPad PRISM 7). P values were generated using the Wilcoxon signed
rank and Wilcoxon-Mann Whitney tests (STATA/IC 14.2). Scatter plots showing reactivity
between P. knowlesi recombinant antigens and P. vivax MSP1-19 were created using STATA
(Fig 4) and dot plots showing reactivity to P. knowlesi recombinant antigens were created
using GraphPad PRISM (Fig 5 and S4 Fig). Final optical density (OD) values were obtained by
Fig 3. SDS-PAGE of purified recombinants. Lane 1: SERA3 ag1; Lane 2: SERA3 ag2; Lane 3: SSP2/TRAP and Lane 4:
TSERA2 ag1. Band sizes are indicated on one side in kDa (Fermentas PageRuler Prestained Protein Ladder). Samples
were ran under reducing conditions at approximately 0.4 mg/ml per lane on a 4–20% gradient gel (NuPAGE, BioRad)
and stained with Coomassie Blue (BioSafe, BioRad). The arrows and asterisks indicate the protein monomers and
aggregates, respectively.
https://doi.org/10.1371/journal.pntd.0006457.g003
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Fig 4. Endemic and P. knowlesi-negative sera reactivity to Plasmodiumknowlesi-specific antigens. Scatter plots showing sera reactivity to: P. vivax MSP1-19
with P. knowlesi SERA3 ag1 (column 1), SERA3 ag2 (column 2), SSP2/TRAP (column 3) and TSERA2 ag1 (column 4) antigens. Sera samples from P. knowlesi-
negative controls n = 55 (row 1; PHE UK malaria naïve (blue), Ethiopian children (red)) and Malaysian hospital case sera samples from days 0 (n = 92), 7 (n = 72)
and 28 (n = 77) of diagnosis (rows 2–4, respectively). The red line in each graph represent the cut off values for the respective P. knowlesi antigen and was
calculated based on Public Health England negative control sera samples (average ODs ± (3xSD)): The vertical cut off line is based on PvMSP1-19 = 0.501. The
horizontal cut off line for the P. knowlesi antigens were based on the following values: SERA3 ag1 = 0.292; SERA3 ag2 = 0.366; SSP2/TRAP = 0.322 and TSERA2
ag1 = 0.208.
https://doi.org/10.1371/journal.pntd.0006457.g004
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subtracting blank OD values, reducing background reactivity. Cut off values for each P. know-
lesi-specific antigen were calculated based on the average ODs of Public Health England nega-
tive control sera samples ± (3xSD).
Ensemble boosted regression trees were fit to determine predictive power of antibody
responses for classification of P. knowlesi exposure. To quantify uncertainty around estimates,
100 datasets were assembled including all seronegative individuals from the malaria unexposed
population and an equal number of randomly selected P. knowlesi seropositive individuals
(from all time points). All models were fit using stratified 10-fold cross validation with model
predictive ability assessed by the area under the receiver operating curve (AUC). The learning
rate was set at 0.001 and tree complexity set at 4, to allow for interactions within the dataset.
Contribution of responses to each antigen to models was assessed using relative variable
importance as described by Elith et. al.[39]. In this method, the relative importance of individ-
ual predictor variables is calculated as the number of times a variable is selected for splitting,
weighted by the squared improvement to the model and averaged over all trees and scaled to
100%. Boosted regression tree analysis was completed in R statistical software (v 3.4.2) using
the gbm package.
Amino acid sequence alignments were generated using MUltiple Sequence Comparison by
Log-Expectation (MUSCLE) (http://www.ebi.ac.uk/Tools/msa/muscle/) [22].
Results
In silico identification, design and expression of target sequences
Sequences associated with known immunological markers in P. falciparum were selected
based on existing evidence (AMA1 [17, 40], MSP1 [40, 41], SSP2/TRAP [42] and SERA anti-
gens [20, 43]), by interrogating existing P. knowlesi databases[21, 44] and supporting literature
[45] (Fig 1). AMA1 is expressed in the micronemes of both the merozoite (invasive asexual
blood stage) and sporozoite (invasive pre-erythrocytive stage) forms [17]. MSP1 is a major
protein located on the surface of the merozoite[41]. SSP2/TRAP is also expressed on the sur-
face of the sporozoite forms [42], and the SERA antigens are soluble parasitophorous vacuole
proteins [20, 43]. Each sequence was processed using available in silico analytical tools (Fig 1).
Gene3D [46] and SMART (http://smart.embl-heidelberg.de/) were used to obtain domain pre-
diction information for each gene which helped with the design of truncated fragments (Fig
2). This approach ensured that the design of truncated sequences properly accounted for the
presence of any potential domains within each sequence, avoiding unintended truncation of
domains which could impact on the solubility of the recombinant proteins. To ensure that
expressed products would be specific for P. knowlesi, target sequences were interrogated multi-
ple times using the BlastP algorithm [47] against both the Plasmodium specific (Plasmodb:
https://is.gd/XOs7vd [21]) and non-redundant databases (NCBI: https://is.gd/MzISez).
Maximum likelihood phylogenetic trees were constructed using the P. knowlesi H reference
strain, highlighting the relationship of each gene between Plasmodium species (S1A–S1E Fig).
Specifically, for both PvAMA1 (bootstrap value: 100%) and PvMSP1-19 (bootstrap value:
87%), there is a strong relationship between different Plasmodium species, particularly between
P. knowlesi and P. vivax (S1A Fig), highlighted further by corresponding near identical amino
acid alignments (S2A Fig). Amino acid alignments were generated using available sequences
for human-pathogenic Plasmodium spp., which clearly highlight the level of sequence identity
for both genes between P. knowlesi and P. vivax (S2A–S2E Fig). Although the bootstrap value
strongly supports the grouping of P. knowlesi with P. vivax and P. simiovale (P. simiovale was
used when data for P. ovale was lacking) (S2C–S2E Fig; bootstrap value: 100%), the alignments
for SSP2/TRAP and the SERA antigens (PKNH_0413400 and PKNH_0413500), help identify
Novel P. knowlesi serological tools
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regions specific for P. knowlesi (S2C–S2E Fig). Based on these screens, any sequences showing
high amino acid sequence identity to other Plasmodium spp., specifically P. ovale, P. malariae,
P. falciparum and P. vivax, were re-edited to focus on P. knowlesi-specific regions only, where
possible. All the antigens were expressed in Escherichia coli as soluble products with final yields
ranging from 11.9–20.5 mg/L (Fig 3, Table 1).
Based on their predicted molecular masses (including the GST tag), SDS PAGE analysis of
the purified proteins clearly suggested multimerisation of the purified products (both mono-
mer and dimer) (Fig 3 and Table 1). The Coomassie stained profiles also illustrated that there
is very little non-specific degradation of the recombinant proteins (Fig 3), suggesting that the
proteins are stable under the conditions used. The protein sizes for each protein were larger
than predicted, so called “gel shifting” when ran on SDS PAGE, which is not uncommon. All
though not fully explained for all proteins classes evidence suggests that the presence of acidic
Fig 5. Serial fold increase in antibody reactivity for each antigen following treatment of knowlesi malaria. (a) SERA3 ag1, (b) SERA3 ag2, (c) SSP2/TRAP
and (d) TSERA2 ag1. Asterisks indicate level of significance, ns denotes non-significant values (p0.0001 ; p0.001 ; p0.01 ; p0.05  and p>0.05 ns).
https://doi.org/10.1371/journal.pntd.0006457.g005
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residues, net hydropathy or protein aggregation can reduce the effectiveness of SDS in altering
the charge, and therefore the migration of proteins through the gel [48, 49]. The fact that all
four protein constructs exhibited signs of protein aggregation supports the suggestion that
aggregation may affect protein migration on polyacrylamide gels (Fig 3 and Table 1). By way
of further validation each protein construct was sequence verified to confirm each sequence
and the position of the stop codons to ensure that the departure from the predicted sizes was
not due to sequence errors in the construct.
The results of the Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) confirmed
that both the SERA3 and TSERA2 candidate genes were actively transcribed in the blood stage
(S3 Fig). By contrast, SSP2/TRAP, a sporozoite stage along with the PkCTRP and PkCSP pre-
erythrocytic stage controls, were negative by RT-PCR (S3 Fig).
SNP analysis: Capturing polymorphic epitopes in target genes
The existence of three major subpopulations of P. knowlesi have been recently described, two
associated with clinical human infections from separate macaque species reservoir hosts and
the third from long-term laboratory isolates [50]. The presence of amino acid polymorphisms
biased towards a single cluster would likely limit the utility of any reagents generated to func-
tion as P. knowlesi-specific, for all P. knowlesi-strains. Therefore, we characterised the presence
of SNPs associated with the clusters, focussing on non-synonymous positions within the P.
knowlesi-specific truncated constructs. S4 Table summarises both the synonymous and non-
synonymous SNPs associated with the three clusters (S5–S8 Tables shows the raw SNP data for
all four constructs; SERA3 Ag1, SERA3 Ag2, SSP2/TRAP and TSERA2 respectively). For all
antigens, the vast majority of the non-synonymous SNPs lie in regions not covered by the anti-
gen design. By omitting the majority of these cluster-specific SNPs we hoped to avoid segrega-
tion of detectable antibodies according to the defined clusters. The relevance of these genetic
clusters in the context of immunity, and the potential relevance to host preferences is yet to be
defined.
Serum reactivity to recombinant antigen panel
Serum samples were collected from 97 Malaysian adults and children hospitalised with P.
knowlesi malaria on day of diagnosis (day 0), 7 and 28 days post-treatment. Hospital case sam-
ples were assayed by enzyme-linked immunosorbent assay (ELISA) using the P. knowlesi-spe-
cific protein panel. Ethiopian non- P. knowlesi malaria endemic children’s sera (n = 26) and
adult UK malaria naïve sera (n = 29) were used as a P. knowlesi-negative control panel. The P.
knowlesi-negative malaria endemic controls were all reactive with the PvMSP1-19 antigen due
to previous P. vivax exposure. The malaria naïve controls showed no reactivity to any of the
antigens tested (Fig 4, top row and S4 Fig) (SERA3 ag1 OD = 0.124; SERA3 ag2 OD = 0.131;
SSP2/TRAP OD = 0.117; TSERA2 ag1 OD = 0.118). With the exception of one weakly positive
sample to SERA3 ag 1 and SSP2/TRAP, there was no other detectable antibody reactivity in
the control group to the P. knowlesi-specific antigens (Fig 4). Antibody reactivity to all four
antigens appeared to peak at day 7 (Figs 4 and 5 and S4 Fig), although prevalence of antibody
responses to SERA3 antigen 1, PkSSP2 and TSERA2 antigen 1 remained relatively low (18.1%
(13/72); 33.3% (45/72) and 43.1% (31/72) respectively) (Fig 4, columns 1, 3 and 4), compared
to SERA 3 antigen 2 (63.8% (46/72)). The PkSERA3 antigen 2 had a higher prevalence com-
pared to controls at all time-points (p<0.001) (Fig 4 and S4 Fig). Antibody responses mea-
sured at day 7 and 28 to SERA3 antigen 2 demonstrated a significant increase when compared
to day 0 (p<0.001 for both comparisons), with fold changes as high as 50 observed for some
samples (Fig 5). In comparison, the fold changes observed in serum responses to the TSERA2
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antigen 1 (day 7 and 28; p =<0.001 and p = 0.005 respectively), SERA3 antigen 1 (day 7;
p = 0.008), and PkSSP2 (day 7 and 28; p = 0.001 and p = 0.013), although statistically signifi-
cant had comparatively lower fold changes with a maximum of 15 (Fig 5).
Identification of P. knowlesi exposed individuals
To assess the predictive ability of responses to these antigens to identify P. knowlesi exposed indi-
viduals, we used boosted regression tree analysis, an ensemble modelling method combining
aspects of machine learning and statistical analysis shown to have strong predictive performance
and reliable identification of variable importance [39]. Similar data-adaptive statistical models are
increasingly being used for classification and identification of patterns in large datasets and have
previously been applied to identify predictive antigens [51]. Although the samples size is small,
boosted regression trees have been used for classification with similarly small training data sets
[39]. To further compensate for the small dataset, we fitted 100 models of random samples of
equal numbers of sero-positive and sero-negative samples within this training dataset and cross-
validated these model predictions. Out of the 100 models fitted for randomly sampled equal num-
bers of exposed and unexposed individuals, the median classification accuracy was 88.9% (IQR:
86.1–91.3%), calculated as the cross-validated area under the receiver operator curve (AUC). Rela-
tive variable importance was calculated for all models. SERA3 antigen 2 contributed most to the
models (median relative variable importance: 50.4% (IQR 43.3–61.4%)), followed by TSERA2
antigen 1, PkSSP2/TRAP and SERA3 antigen 1 (Fig 6).
Fig 6. Relative variable importance of responses to each antigen from 100 boosted regression tree models predicting P.
knowlesi seropositivity. Median values for the relative variable importance and interquartile ranges are shown for all antigens
tested: SERA3 ag 1 (4.8%; IQR 2.5–7.8%); SERA3 ag 2 (50.4%; IQR 43.3–61.4%); PkSSP2/TRAP (6.5%; IQR 3.7–11.8%) and TSERA
ag 1 (34.2%; IQR 26.2–41.8%).
https://doi.org/10.1371/journal.pntd.0006457.g006
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Discussion
P. knowlesi is a naturally occurring infection of long-tailed and pig-tailed macaques, histori-
cally associated with forested areas of Southeast Asia [52]. Increased deforestation of their nat-
ural habitat is thought to have led to increased interaction between macaques and the human
population in endemic areas [53]. Changes in village level forest cover and historical forest loss
has been associated with an increase in P. knowlesi clinical cases in Sabah [54], with malaria
caused by P. knowlesi increasingly reported in Southeast Asia [8]. Conversely, there has also
been a steady decline in the prevalence of P. falciparum and P. vivax infections in the same
region [55].
The recent efforts of the malaria community towards achieving malaria elimination means
that tools to help monitor the impact and effectiveness of intervention strategies are an urgent
requirement [56]. The development of species-specific tools for P. knowlesi would allow accu-
rate assessment of the levels and geographical limits of infection with this zoonotic species
[57]. There is an urgent need to develop a comprehensive discovery strategy to help identify P.
knowlesi unique antigenic markers of exposure in order to further characterise this organism
and develop stronger and better identification methods.
Currently, there are no specifically designed biomarkers for the serosurveillance of P. know-
lesi infections. Recombinant proteins are available [PkCSP [58], PkAMA1 [59], PkDBP [60],
PkSPATR [15], PkLDH [61], Pk1-Cys peroxiredoxin [62], Pk knowpains [63], PkMSP1-42
[64], PkMSP1-33 [65], PkMSP1-19 [66], Pk tryptophan-rich antigens (PkTrags) [67], PkMSP3
[68] and PkSBP1 [69], but are limited in number and are generally not species-specific. As a
result, their utility as serological diagnostic tools is generally secondary to their original design.
The reported level of amino acid sequence conservation to other Plasmodium spp. in some
currently available P. knowlesi proteins is > 60% across large stretches of continuous sequence.
Such reagents could not be specific to P. knowlesi [70] and would be unable to reliably discrim-
inate between antibody responses to different parasite species in co-endemic settings.
High levels of amino acid identity (83%) between PvMSP1-19 and PkMSP1-19, meant we
were unable to use these reagents to dissect the species-specific immune responses due to the
inevitable cross-reactive antibody responses. This is consistent with a proportion (48.9% (45/
92)) of the confirmed P. knowlesi-exposed clinical samples in this study reacting with
PvMSP1-19 at day 0, although it is unknown whether these participants had previously been
exposed to P. vivax. However, this limitation simply reflects the paucity of available serological
reagents for use in assessing exposure to infection, a deficit this study aims to address.
Although the small number of clinical case samples do not give sufficient statistical power to
assess either the duration of antibody responses to the panel of antigens or population-level
exposure, the P. knowlesi clinical case samples represent a unique dataset with which to vali-
date the immunogenicity of our antigen panel.
The use of the boosted regression tree model was able to discriminate between P. knowlesi
exposed and unexposed individuals for the purposes of classification of seropositivity rather
than to assess individual-level risk factors. While this dataset is sufficient for classification as
exposed or unexposed, it is not sufficiently large enough to stratify by age, gender or previously
reported malaria status. In order for us to assess these types of risk factors, we would first need
to apply an approach (using known negatives, mixture or probability models) to classify anti-
body responses as sero-positive or sero-negative and then assess risk factors within the popula-
tion. Based on this result the PkSERA 3 antigen 2 recombinant was used to survey ~2500
samples across three site; Limbuak, Pulau Banggi and Matunggung, Kudat, Sabah, Malaysia
and Bacungan, Palawan, the Philippines [71]. One of the key elements from this study using
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this reagent was the indication of community level patterns of exposure that differed markedly
from reported cases, with higher levels of exposure among women and children [71].
The panel of reagents developed for this study focussed on immunologically relevant ortho-
logous targets previously described in P. falciparum. The serine repeat antigen (SERA) family
had previously attracted attention as a source of both drug and vaccine candidates [72]. In P.
falciparum, SERA 5 is the most abundant parasitophorous vacuole protein and is essential to
blood stage growth of the parasite [73], with antibodies against this antigen thought to inhibit
parasite growth [74]. Although possessing a papain-like enzymatic domain, recent evidence
suggests that the protein plays a non-enzymatic role [73]. SERA 3 has also been shown to be a
highly immunogenic antigen with an important, although not essential role in the erythrocytic
cycle [75] and has also been implicated as having a role in liver stage merozoite release in P.
berghei [76]. Similarly, evidence for the sporozoite surface protein 2 (SSP2/TRAP) suggested
an immunogenic antigen involved in protection from disease in mice [77]. Although we were
unable to confirm active transcription of SSP2/TRAP due to the lack of available material, we
were able to validate active transcription of both the SERA3 and TSERA2 candidate genes.
Collectively, the evidence provided by studies on Plasmodium supports the design of seroepi-
demiology tools based on these targets. Despite the targeted approach used in designing the
recombinant constructs, the SERA3 antigen 2 construct was by far the most promising candi-
date. The differences in the performances of the antigens could be due to a number of factors:
(1) variation in the inherent immunogenicity of the regions selected, (2) variations in the
expression status of the P. knowlesi antigens compared to P. falciparum or (3) the loss of immu-
noreactive epitopes due to the truncation of the protein.
There are a number of potential limitations of the study. The small sample size of the clini-
cal samples used prevented detailed analysis of the samples, such as monitoring the impact of
factors such as age, on the profile of reactivity to the reagents under test. In addition, the lack
of repeated samples per individual (i.e. longitudinal samples) prevented us from investigating
the longevity of antibody responses to each target, across individuals and age groups. The
availability of supporting biological information on P. knowlesi, such as functional data, tran-
scriptional or RNA seq data would have helped with the rational selection of additional candi-
dates for further study and the design recombinant tools.
This is the first study to describe the development a panel of P. knowlesi-specific serological
tools using freely available in silico software. We have demonstrated the importance of target-
ing species-specific reagents at the amino acid level and highlighted the potential of such pro-
teins as serosurveillance tools. Using these tools we have been able to measure specific
immune responses to these reagents and described the change in antibody profile following
treatment. As such, we have already demonstrated the utility of the SERA3 antigen 2 reagents
as a potential seroepidemiological tool. Studies are also currently in development to expand
the existing panel of P. knowlesi species-specific reagents to identify additional serological
tools. Beyond this we envisage employing high throughput antigen discovery approaches such
as the protein microarray to help identify additional important targets of immunity [51, 78].
Further validation of the SERA3 antigen 2 at the population level has recently been performed
[71]. Further studies are also planned to characterise the wider immunoglobulin responses,
such as IgG subclasses and IgM, to these and future antigens.
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